Authors

David P. Labbé, Dana-Farber Cancer Institute; Harvard Medical School; McGill University; Research Institute of the McGill University Health Centre
Giorgia Zadra, Dana-Farber Cancer Institute; Brigham and Women's Hospital
Meng Yang, Harvard T.H. Chan School of Public Health
Jaime M Reyes, Harvard Medical School
Charles Y Lin, Baylor College of Medicine
Stefano Cacciatore, International Centre for Genetic Engineering and Biotechnology
Ericka M. Ebot, Harvard T.H. Chan School of Public Health
Amanda L. Creech, Broad Institute of MIT and Harvard University
Francesca Giunchi, S-Orsola-Malpighi Hospital
Michelangelo Fiorentino, S-Orsola-Malpighi Hospital
Habiba Elfandy, Dana-Farber Cancer Institute
Sudeepa Syamala, Dana-Farber Cancer Institute
Edward D. Karoly, Metabolon
Mohammed Alshalalfa, Decipher Biosciences
Nicholas Erho, Decipher Biosciences
Ashley Ross, Johns Hopkins Medical Institutions
Edward M. Schaeffer, Northwestern University Feinberg School of Medicine
Ewan A. Gibb, Decipher Biosciences
Mandeep Takhar, Decipher Biosciences
Robert B. Den, Thomas Jefferson UniversityFollow
Jonathan Lehrer, Decipher Biosciences
R. Jeffrey Karnes, Mayo Clinic
Stephen J. Freedland, Cedars-Sinai Medical Center; Durham Veteran Affairs Medical Center
Elai Davicioni, Decipher Biosciences
Daniel E. Spratt, The University Of Michigan
Leigh Ellis, Dana-Farber Cancer Institute; Brigham and Women's Hospital; Broad Institute of MIT and Harvard University
Jacob D. Jaffe, Broad Institute of MIT and Harvard University
Anthony V. DʼAmico, Dana-Farber Cancer Institute; Brigham and Women's Hospital; Harvard Medical School
Philip W. Kantoff, Dana-Farber Cancer Institute; Harvard Medical School; Memorial Sloan Kettering Cancer Center
James E. Bradner, Dana-Farber Cancer Institute; Harvard Medical School
Lorelei A. Mucci, Harvard T.H. Chan School of Public Health; Brigham and Women's Hospital; Harvard Medical School
Jorge E. Chavarro, Harvard T.H. Chan School of Public Health; Brigham and Women's Hospital; Harvard Medical School
Massimo Loda, Dana-Farber Cancer Institute; Brigham and Women's Hospital; Broad Institute of MIT and Harvard University; Weil Cornell Medicine
Myles Brown, Dana-Farber Cancer Institute; Harvard Medical School

Document Type

Article

Publication Date

9-25-2019

Comments

This article is the author’s final published version in Nature Communications, Volume 10, Issue 1, September 2019, Page 4358.

The published version is available at https://doi.org/10.1038/s41467-019-12298-z. Copyright © Labbé et al.

Abstract

Systemic metabolic alterations associated with increased consumption of saturated fat and obesity are linked with increased risk of prostate cancer progression and mortality, but the molecular underpinnings of this association are poorly understood. Here, we demonstrate in a murine prostate cancer model, that high-fat diet (HFD) enhances the MYC transcriptional program through metabolic alterations that favour histone H4K20 hypomethylation at the promoter regions of MYC regulated genes, leading to increased cellular proliferation and tumour burden. Saturated fat intake (SFI) is also associated with an enhanced MYC transcriptional signature in prostate cancer patients. The SFI-induced MYC signature independently predicts prostate cancer progression and death. Finally, switching from a high-fat to a low-fat diet, attenuates the MYC transcriptional program in mice. Our findings suggest that in primary prostate cancer, dietary SFI contributes to tumour progression by mimicking MYC over expression, setting the stage for therapeutic approaches involving changes to the diet.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

31554818

Language

English

Share

COinS